Comparing four ovarian reserve markers - Associations with ovarian response and live births after assisted reproduction

Acta Obstetricia et Gynecologica Scandinavica

Volumn 94, Issue 10, 2015, Pages 1056-1063

  Brodin, Thomas ^a,b   Hadziosmanovic, Nermin ^c   Berglund, Lars ^c   Olovsson, Matts ^a   Holte, Jan ^a,b,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Carl von Linne Kliniken   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^d Swedish University of Agricultural Sciences   (Sweden)

Author keywords

anti M llerian hormone; Antral follicle counts; follicle stimulating hormone; in vitro fertilization; menstrual cycle length; ovarian reserve tests

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

ADULT; AGE; ARTICLE; BIRTH RATE; COHORT ANALYSIS; ESTRUS CYCLE; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARIAN FUNCTION TEST; OVARIAN RESERVE; OVARIAN RESPONSE; OVARY FOLLICLE; OVARY FUNCTION; OVARY HYPERSTIMULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PRIVATE HOSPITAL; RISK ASSESSMENT; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; CYTOLOGY; EPIDEMIOLOGY; OVULATION INDUCTION; PHYSIOLOGY; PROCEDURES;

ADULT; ANTI-MULLERIAN HORMONE; COHORT STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LIVE BIRTH; LUTEINIZING HORMONE; OVARIAN FOLLICLE; OVARIAN FUNCTION TESTS; OVARIAN RESERVE; OVULATION INDUCTION; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84941737775     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12710     Document Type: Article

References (35)

1. Ruess ML, Kline J, Santos R, Levin B, Timor-Tritsch I. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol. 1996;174:624-7.
2. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065-71.
3. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651-4.
4. Weghofer A, Feichtinger W. The forgotten variable: impact of luteinizing hormone on the prediction of ovarian reserve. Fertil Steril. 2006;85:259-61.
5. Brodin T, Bergh T, Berglund L, Hadziosmanovic N, Holte J. Menstrual cycle length is an age-independent marker of female fertility: results from 6271 treatment cycles of in vitro fertilization. Fertil Steril. 2008;90:1656-61.
6. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91:705-14.
7. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update.2013;19:26-36.
8. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685-718.
9. Verhagen TE, Hendriks DJ, Bancsi LF, Mol BW, Broekmans FJ. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum Reprod Update. 2008;14:95-100.
10. Broer SL, Mol B, Dolleman M, Fauser BC, Broekmans FJ. The role of anti-Mullerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol. 2010;22:193-201.
11. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles - implications for individualization of therapy. Hum Reprod. 2007;22:2414-21.
12. Brodin T, Bergh T, Berglund L, Hadziosmanovic N, Holte J. High basal LH levels in combination with low basal FSH levels are associated with high success rates at assisted reproduction. Hum Reprod. 2009;24:2755-9.
13. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M, Bergh T. Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. Fertil Steril. 2011;96:594-9.
14. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98:1107-14.
15. Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20:560-70.
16. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77:357-62.
17. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18:323-7.
18. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318-23.
19. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17:46-54.
20. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95:170-5.
21. Rosen MP, Johnstone E, McCulloch CE, Schuh-Huerta SM, Sternfeld B, Reijo-Pera RA, et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril. 2012;97:238-43.
22. Holte J. The construction and validation of a prediction model to minimize twin rates at preserved live birth rates in ART. Stockholm: ESHRE, 2011.
23. Huber M, Hadziosmanovic N, Berglund L, Holte J. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertil Steril. 2013;100:1270-6.
24. van der Steeg JW, Steures P, Eijkemans MJC, Habbema JDF, Hompes PGA, Broekmans FJ, et al. Pregnancy is predictable: a large-scale prospective external validation of the prediction of spontaneous pregnancy in subfertile couples. Hum Reprod. 2007;22:536-42.
25. Biasoni V, Patriarca A, Dalmasso P, Bertagna A, Manieri C, Benedetto C, et al. Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF. Reprod Biol Endocrinol. 2011;9:112.
26. Broer SL, Dolleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013;100:420-9.e7.
27. Li HW, Lee VC, Ho PC, Ng EH. Ovarian sensitivity index is a better measure of ovarian responsiveness to gonadotrophin stimulation than the number of oocytes during in-vitro fertilization treatment. J Assist Reprod Genet.2014;31:199-203.
28. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26:1768-74.
29. Gianaroli L, Magli MC, Ferraretti AP, Fortini D, Tabanelli C, Gergolet M. Gonadal activity and chromosomal constitution of in vitro generated embryos. Mol Cell Endocrinol. 2000;161:111-6.
30. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83:291-301.
31. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103-7.
32. Rustamov O, Pemberton PW, Roberts SA, Smith A, Yates AP, Patchava SD, et al. The reproducibility of serum anti-Mullerian hormone in subfertile women: within and between patient variability. Fertil Steril. 2011;95:1185-7.
33. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688-701.
34. Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem. 2011;48:370-3.
35. Rustamov O, Smith A, Roberts SA, Yates AP, Fitzgerald C, Krishnan M, et al. Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod. 2012;27:3085-91.